show episodes
 
Artwork

1
340B Unscripted

SpendMend Pharmacy

Unsubscribe
Unsubscribe
Monthly+
 
Pharmacists and healthcare industry leaders Rob ‘Hoopi’ Nahoopii PharmD, MS, ACE and Greg Wilson PharmD, BCPS, ACE dive deeply into the complicated and contentious 340B Program as well as other pressing Pharmacy matters. Special guests and industry experts pop in frequently to add insights from all sides of the discussion. If you serve in the pharmacy sector, this podcast is a must-listen!
  continue reading
 
340B Insight provides members and supporters of 340B Health with timely updates and discussions about the 340B drug pricing program. The podcast helps listeners stay current with and learn more about 340B to help them serve their patients and communities and remain compliant. We publish new episodes twice a month, with news reports and in-depth interviews with leading health care practitioners, policy and legal experts, public policymakers, and our expert staff.
  continue reading
 
Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report’s newsroom for a candid, insider’s perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
  continue reading
 
Artwork
 
Short insights into the 340B world, primarily focusing on audits...but in no way limited to just audits. From the Godfather of 340B who created the first 340B Splitting software, AutoSplit 340B, which became Talyst and then Verity Solutions.
  continue reading
 
Maintaining a compliant 340B Program can be daunting and complex. Staying current with the latest clinical, pharmaceutical and industry related news is essential in order to make informed decisions and provide the best care possible. Listen to leading 340B, technology and pharmacy professionals who provide clinical insights and the latest information to help support your 340B program. Learn more at 340BInsider.com
  continue reading
 
For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare. RealPharma podcast aims to challenge your viewpoints, deepen your understanding of the pharma world beyond the headlines, and explore emerging trends in medical innovation.
  continue reading
 
If you’re concerned about revenue at your hospital, then The Hospital Finance podcast is your go-to source for information and insights that can help you protect and enhance the revenue your hospital has earned. From regulatory changes to revenue cycle optimization, readmissions to bundled payments, you’ll get important perspectives, news and strategies from leading experts in healthcare finance. For show notes and additional resources from BESLER, visit https://www.besler.com/podcasts
  continue reading
 
Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.
  continue reading
 
Join Chuck Buck every Monday when he welcomes RACmonitor contributing editors and special guests for the latest regulatory audit news and information from CMS, OIG and OMHA. And gain valuable context and perspective that can only be found when you’re listening to the long-running and popular Monitor Mondays. Register to attend live here: https://racmonitor.medlearn.com/racmonitor/podcasts/
  continue reading
 
Welcome to the TKG PACT Executive Briefing, where in 3-minutes we highlight healthcare’s critical market access issues, policies, challenges, or trends. This resource offers condensed, 3-minute episodes of market insights. Our passion is on achieving the Quintuple Aim of enhancing patient experience, improving population health, reducing costs, improving the work life of health care providers and staff., and enhancing health equity in all aspects of care delivery. I’m Dr. Warren Smedley, tha ...
  continue reading
 
JAMA Health Forum is a peer-reviewed, open-access JAMA Network journal focused on health policy. The journal publishes original research, evidence-based reports, and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity, and reform. The podcast highlights new articles and their authors as well as the latest news in health policy for a broad audience interested in improving health and health c ...
  continue reading
 
American Healthcare Entrepreneurs and Execs you might want to know. Talking. Relentless Health Value is a weekly interview podcast hosted by Stacey Richter, a healthcare entrepreneur celebrating fifteen years in the business side of healthcare. This show is for leaders in pharma, devices, payers, providers, patient advocacy and healthcare business. It's for health industry innovators, entrepreneurs or wantrepreneurs or intrapreneurs. Relentless Healthcare Value is the show for you if you wan ...
  continue reading
 
Triage: Rapid Legal Lessons for Busy Health Care Professionals has been created by K&L Gates to convey information about developments in health law through short podcasts. If you work in the health care industry, you have grown accustomed to frequent changes in laws and regulations. On some days, it may seem like an insurmountable task to keep up with every change, especially as a new presidential administration and new policies take shape. The K&L Gates Health Care practice will regularly c ...
  continue reading
 
Loading …
show series
 
Dr. Gavin Magaha, Senior Director for External Affairs and Policy at Kalderos, describes the 340B drug discount program created in 1992 to help safety net healthcare providers obtain discounted drugs. Over time, this program has grown in complexity, and issues have arisen around duplicate discounts where Medicaid rebates are involved. The current 3…
  continue reading
 
Within the past few weeks, drugmaker Johnson & Johnson went head-to-head with 340B hospitals and the federal government over the company’s plan to stop paying upfront 340B discounts on two of its top-selling drugs. 340B Health Senior Counsel Amanda Nagrotsky joins us to explain how that conflict played out. HRSA Warns Johnson & Johnson of Strong Pu…
  continue reading
 
In this episode, Greg and Rob discuss the various uses of 340B billing modifiers. They’ll discuss some general considerations around what billing modifiers are used for, highlight differences between hospital/clinic and pharmacy billing in terms of applying correct modifiers, and debate different aspects of Medicaid and Medicare billing modifier re…
  continue reading
 
In episode 2, host Ted Slafsky, along with Will Newton and Bella Czajkowski, recap major news impacting the 340B program, including the future of manufacturer efforts to convert 340B to a rebate, Sen. Bill Cassidy’s latest inquiry into two drugmakers, pushback from bipartisan House members to the rebate proposal federal 340B legislation and key sta…
  continue reading
 
A major drug company’s attempt to turn 340B drug pricing program discounts into rebates made big headlines in recent weeks. Maureen Testoni, president and CEO of 340B Health, will review how this potentially major upheaval came about, how 340B stakeholders responded, and how the drugmaker backed off after the federal government threatened it with m…
  continue reading
 
In this episode, Dr. Na-Ri Oh and Ian Wendt sit down with Philip Vyt, a renowned expert in omnichannel strategy and founder of Shyft, a consultancy specializing in omnichannel approaches for biopharma. They delve into the key concepts behind omnichannel and its distinction from multichannel, emphasizing the centrality of healthcare professionals (H…
  continue reading
 
David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, th…
  continue reading
 
David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, th…
  continue reading
 
In this episode, host Stacey Richter delves into the complexities of the Third Party Administrator (TPA) Request for Proposal (RFP) process with guest Claire Brockbank from 32BJUnion. The discussion highlights the critical role of contracts in managing health plans effectively and the potential pitfalls of accepting contracts crafted by TPAs withou…
  continue reading
 
Send us a text The topic for this week’s @The Kinetix Group PACT Executive Briefing is “The FACT Standards for Immune Effector Cells.” These accrediting standards were developed by the Foundation for the Accreditation of Cellular Therapy (FACT), using a consensus of experts to promote quality medical and laboratory practice across the field of immu…
  continue reading
 
Dr. Gavin Magaha, Senior Director for External Affairs and Policy at Kalderos, describes the 340B drug discount program created in 1992 to help safety net healthcare providers obtain discounted drugs. Over time, this program has grown in complexity, and issues have arisen around duplicate discounts where Medicaid rebates are involved. The current 3…
  continue reading
 
Chris Hart, Co-Founder, CEO, and President of Creyon Bio, is focused on engineering drugs rather than just discovering them through serendipity and traditional methods. Creyon is developing oligonucleotide medicines for rare and common diseases by applying AI and big data models of the molecular and genetic basis of diseases to develop safe and eff…
  continue reading
 
Chris Hart, Co-Founder, CEO, and President of Creyon Bio, is focused on engineering drugs rather than just discovering them through serendipity and traditional methods. Creyon is developing oligonucleotide medicines for rare and common diseases by applying AI and big data models of the molecular and genetic basis of diseases to develop safe and eff…
  continue reading
 
The U.S. Department of Justice (DOJ) has reported that one of America’s largest urine drug-testing companies has agreed to pay $27 million to resolve allegations of unnecessary drug testing and illegal remuneration to physicians. The False Claims Act allegations resolved by this settlement were originally brought in three lawsuits filed by whistleb…
  continue reading
 
Krystyna Houser is the Founder of mBIOTA Labs, a company that develops effective and tolerable elemental diets and medical foods for treating gastrointestinal disorders such as IBS, IBD, SIBO, IMO, and Crohn's disease. While short-term liquid elemental diets have been used in the past to treat GI conditions, the formulation has been very unpalatabl…
  continue reading
 
Krystyna Houser is the Founder of mBIOTA Labs, a company that develops effective and tolerable elemental diets and medical foods for treating gastrointestinal disorders such as IBS, IBD, SIBO, IMO, and Crohn's disease. While short-term liquid elemental diets have been used in the past to treat GI conditions, the formulation has been very unpalatabl…
  continue reading
 
The use of care by patients of physicians considered more altruistic differs from the use of care of physicians considered less. Lawrence P. Casalino, MD, PhD, MPH, of Weill Cornell Medicine, discusses his work around this with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD. Related Content: Physician Altruism…
  continue reading
 
In this episode I interview Cora Opsahl from the 32BJ Health Fund to examine the intricate dynamics between fiduciary duties and the entrenched status quo in healthcare. The discussion focuses on the challenges employers face when dealing with anti-competitive contracts and their responsibility to ensure plan expenses are reasonable. Cora Opsahl, m…
  continue reading
 
Dr. Ann Beliën, Chief Executive Officer and Founder at Rejuvenate Biomed, is addressing the underlying biology of aging including mechanisms like mitochondrial health, cell-cell communication and inflammation in order to promote healthy aging. Taking a combination therapy approach, Rejuvenate is using AI-enable drug discovery to address multiple pa…
  continue reading
 
Dr. Ann Beliën, Chief Executive Officer and Founder at Rejuvenate Biomed, is addressing the underlying biology of aging including mechanisms like mitochondrial health, cell-cell communication and inflammation in order to promote healthy aging. Taking a combination therapy approach, Rejuvenate is using AI-enable drug discovery to address multiple pa…
  continue reading
 
Eric Olson, COO and Founder of BetterWay™ by Babson Diagnostics™, reports that traditional blood testing is often seen as inconvenient and unpleasant, causing 40% of people to avoid needed blood tests. Babson has developed a more patient-friendly approach to blood collection using a device that fits on the finger and requires a minimum amount of bl…
  continue reading
 
Eric Olson, COO and Founder of BetterWay™ by Babson Diagnostics™, reports that traditional blood testing is often seen as inconvenient and unpleasant, causing 40% of people to avoid needed blood tests. Babson has developed a more patient-friendly approach to blood collection using a device that fits on the finger and requires a minimum amount of bl…
  continue reading
 
Marylyn Rigby, President and CEO of Bioceptive, focuses on improving women's health technologies. Bioceptive has developed a cervical suction retractor as an alternative to the 200-year-old cervical tenaculum device used to insert IUDs and perform biopsies and other intrauterine procedures. While current procedures are extremely painful, there has …
  continue reading
 
Marylyn Rigby, President and CEO of Bioceptive, focuses on improving women's health technologies. Bioceptive has developed a cervical suction retractor as an alternative to the 200-year-old cervical tenaculum device used to insert IUDs and perform biopsies and other intrauterine procedures. While current procedures are extremely painful, there has …
  continue reading
 
In this episode, Dr. Na-Ri and Ian Wendt welcome back Kristiaan Rawlings, from EPM Scientific to discuss the latest trends in pharma and biotech hiring. They explore the key drivers of hiring, the impact of AI and advanced analytics, and the evolving expectations of candidates. Kristiaan emphasizes the importance of change agents in the industry an…
  continue reading
 
Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics, a company with expertise in reducing pain and addressing opioid use disorder and fatal overdose from fentanyl. Elysium has developed O2P, Oral Overdose Protection, a technology that aims to control the impact of opioids and reduce the risk of use disorder or a fatal overdose. SOOPR is a resc…
  continue reading
 
Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics, a company with expertise in reducing pain and addressing opioid use disorder and fatal overdose from fentanyl. Elysium has developed O2P, Oral Overdose Protection, a technology that aims to control the impact of opioids and reduce the risk of use disorder or a fatal overdose. SOOPR is a resc…
  continue reading
 
In this Spotlight Episode host Stacey Richter discusses the management of oncology side effects with Dan Nardi, CEO of Reimagine Care. Highlighting the challenges cancer patients face, especially following chemotherapy which often leads to nausea and readmissions, the conversation delves into how Reimagine Care facilitates at-home integrative cance…
  continue reading
 
Dr. Boris Reznik, Chairman and CEO of Immorta Bio, was founded to explore longevity and life extension technologies inspired by the discovery that aged cells can be reprogrammed to become younger ones. The company has a cellular rejuvenation platform that uses the patient's cells and senolytic immunotherapy to help the immune system target and remo…
  continue reading
 
Loading …

Quick Reference Guide